Walleye Capital
VKTX icon

Walleye Capital’s Viking Therapeutics VKTX Stock Holding History

Walleye Capital’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$538K Sell
13,800
-19,200
-58% -$620K ﹤0.01% 2655
2026
Q1 		$1.07M Sell
33,000
-67,800
-67% -$2.18M ﹤0.01% 2012
2025
Q4 		$3.55M Buy
100,800
+10,100
+11% +$358K 0.01% 1410
2025
Q3 		$2.38M Buy
90,700
+58,700
+183% +$1.75M 0.01% 1452
2025
Q2 		$848K Sell
32,000
-1,200
-4% -$31.6K ﹤0.01% 2180
2025
Q1 		$802K Sell
33,200
-10,300
-24% -$326K ﹤0.01% 2160
2024
Q4 		$1.75M Sell
43,500
-5,300
-11% -$302K ﹤0.01% 1904
2024
Q3 		$3.09M Buy
48,800
+32,300
+196% +$1.9M 0.01% 1557
2024
Q2 		$875K Buy
16,500
+7,900
+92% +$518K ﹤0.01% 2988
2024
Q1 		$705K Sell
8,600
-28,800
-77% -$1.28M ﹤0.01% 2902
2023
Q4 		$696K Buy
+37,400
New +$489K ﹤0.01% 2677
2023
Q3 		– Sell
-8,600
Closed -$139K – 5356
2023
Q2 		$139K Sell
8,600
-5,300
-38% -$111K ﹤0.01% 3286
2023
Q1 		$231K Buy
+13,900
New +$144K ﹤0.01% 2346

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Walleye Capital's VKTX Position: Q2 2026 in Review

Walleye Capital increased its Viking Therapeutics (VKTX) stake by 147% in Q2 2026, buying an estimated $217K and bringing the position to 11,302 shares worth $441K. The position accounts for ﹤0.01% of the portfolio, ranked #2858.

Walleye Capital first reported a position in VKTX in Q3 2018 and has held it in 18 quarters since. The position peaked at $3.04M in Q4 2025. 436 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • Walleye Capital held 11,302 shares of Viking Therapeutics worth $441K as of Q2 2026.
  • Walleye Capital bought 6,729 Viking Therapeutics shares in Q2 2026, an estimated $217K.
  • Viking Therapeutics made up ﹤0.01% of Walleye Capital's portfolio in Q2 2026, its #2858 holding.
  • Walleye Capital first reported a position in Viking Therapeutics in Q3 2018 and has held it in 18 quarters since.
  • Walleye Capital's Viking Therapeutics position peaked at $3.04M in Q4 2025.
  • 436 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Walleye Capital's 13F filing for Q2 2026, filed 3 Aug 2026.